Translational cancer research最新文献

{"title":"CEBPG demonstrates oncogene functions and modulates the expression of genes involved in cervical cancer related pathways.","authors":"Tingting Qi, Jing Yang, Guzhalinuer Abulizi","doi":"10.21037/tcr-2026-0938","DOIUrl":"10.21037/tcr-2026-0938","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a major cause of female cancer incidence and mortality globally. Targeted therapy shows promise with higher efficacy and fewer side effects, yet effective biomarkers are needed. CEBPG, a bZIP transcription factor, has attracted attention as a potential biomarker and therapeutic target. It promotes tumor growth in various cancers, but its role in cervical cancer is unclear. The aim of this study is to investigate the expression, biological function, and transcriptional regulatory mechanisms of CEBPG in cervical cancer.</p><p><strong>Methods: </strong>This study analyzed CEBPG expression in cervical cancer using The Cancer Genome Atlas (TCGA) data, overexpressed it in HeLa cells, and conducted proliferation, apoptosis, migration, and invasion experiments. RNA sequencing (RNA-seq) revealed CEBPG's transcriptional regulatory network.</p><p><strong>Results: </strong>Our findings revealed that CEBPG expression was significantly higher in cervical cancer than in normal tissues. Overexpression of CEBPG in HeLa cells significantly enhanced proliferation, migration, and invasion while repressing apoptosis. RNA-seq analysis identified numerous differentially expressed genes (DEGs) enriched in pathways critical for tumorigenesis and progression, such as angiogenesis, cell proliferation, and migration. Bioinformatics analysis identified 27 potential transcriptional targets of CEBPG, several of which were associated with poor prognosis and higher expression in cervical cancer tissues.</p><p><strong>Conclusions: </strong>CEBPG may contribute to malignant phenotypes in cervical cancer, potentially through the transcriptional regulation of specific target genes. The high expression of CEBPG in cervical cancer and its demonstrated role in promoting malignancy through transcriptional regulation provide novel insights into the molecular mechanisms of cervical carcinogenesis and progression. This offers directions for further exploration of CEBPG as a potential therapeutic target and biomarker.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"593"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-tolerant persister cells use conserved adaptive transcriptional programs.","authors":"Yu-Chi Chen, Gavin P Robertson","doi":"10.21037/tcr-2026-1168","DOIUrl":"10.21037/tcr-2026-1168","url":null,"abstract":"","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"662"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining Napsin A expression with circulating tumor cell counts for enhanced identification of pulmonary adenocarcinoma in ground-glass nodules.","authors":"Suhong Ruan, Hongjie Yu, Zhenyuan Song, Xiang Zhu, Guangda Yuan, Hongya Xie, Chuanyu Zhang, Tengteng Wei","doi":"10.21037/tcr-2026-1155","DOIUrl":"10.21037/tcr-2026-1155","url":null,"abstract":"<p><strong>Background: </strong>Circulating tumor cells (CTCs) have shown potential for early lung cancer diagnosis, but their sensitivity and isolation yield are currently limited. Napsin A is a sensitive and specific marker for adenocarcinoma diagnosis. Therefore, combining CTC detection with Napsin A expression analysis may provide an accurate method for identifying pulmonary adenocarcinoma in ground-glass nodules (GGNs), which could significantly improve patient survival rates. This study aims to evaluate the diagnostic value of detecting Napsin A‑positive CTCs for identifying pulmonary adenocarcinoma among patients with GGNs.</p><p><strong>Methods: </strong>Peripheral blood samples were collected from 91 patients who had been diagnosed with GGNs. CTCs were captured using an efficient nano-enrichment method, and Napsin A expression was detected through immunofluorescent labeling. The diagnostic value of these metrics for pulmonary adenocarcinoma in GGNs was evaluated using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC).</p><p><strong>Results: </strong>Our findings demonstrate that the number of CTCs in patients in the malignant group was significantly higher than that in the benign group (P<0.001). ROC analysis reveals an AUC of 0.627 for CTC detection alone, with a sensitivity of 63.64% and specificity of 72.46%. However, when CTC counts were combined with Napsin A-positive expression (Napsin A⁺), the diagnostic performance markedly improved: the sensitivity and specificity for detecting lung adenocarcinoma among GGNs rose to 90.91% and 88.41%, respectively, and the AUC increased to 0.918, indicating substantially enhanced discriminatory power.</p><p><strong>Conclusions: </strong>The combination of CTC counting and Napsin A⁺ expression analysis holds promise for the identification of pulmonary adenocarcinoma in GGNs.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"628"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value and molecular mechanisms of <i>Porphyromonas gingivalis</i> infection-associated differentially expressed genes in oral squamous cell carcinoma.","authors":"Qin Song, Youwen Zhang, Xiaodi Wu, Jiakuan Peng, Yihan Zhao, Yanjun Zhang, Xin Chen","doi":"10.21037/tcr-2026-0747","DOIUrl":"10.21037/tcr-2026-0747","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Increasing evidence suggests that Porphyromonas gingivalis (Pg) is associated with oral squamous cell carcinoma (OSCC) development and progression. This study aimed to identify Pg-associated genes with prognostic relevance in OSCC through integrated bioinformatics analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;OSCC-related differentially expressed genes (DEGs) were identified from the The Cancer Genome Atlas (TCGA)-OSCC cohort and intersected with Pg supernatant-associated DEGs from GSE192887. Raw count data were analyzed with DESeq2, whereas transcripts per million (TPM)-transformed expression values were used for downstream visualization and model construction. Weighted gene co-expression network analysis (WGCNA), univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariable Cox modeling were used to develop a seven-gene prognostic signature, which was externally evaluated in GSE41613. Additional analyses examined treatment-associated expression changes in the seven model genes, pairwise correlations among the model genes, and correlations between Pg supernatant-associated differentially expressed gene (PgSDEG)-derived module eigengenes and immune-cell fractions. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed in eight paired OSCC and adjacent non-tumor tissues and in supplemented-brain heart infusion (BHI) vehicle-control and Pg culture-supernatant-treated HOK, HSC-3, and CAL-27 cells.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A prognostic signature comprising &lt;i&gt;CXCL8&lt;/i&gt;, &lt;i&gt;GAST&lt;/i&gt;, &lt;i&gt;HBQ1&lt;/i&gt;, &lt;i&gt;PADI3&lt;/i&gt;, &lt;i&gt;STC1&lt;/i&gt;, &lt;i&gt;TEX19&lt;/i&gt;, and &lt;i&gt;TMEM92&lt;/i&gt; was established. The signature showed limited-to-moderate discrimination in the TCGA training cohort, with 1-, 3-, and 5-year areas under the curve (AUCs) of 0.68, 0.69, and 0.69, respectively, and limited discrimination in the GSE41613 external cohort (AUCs: 0.66, 0.67, and 0.61). Kaplan-Meier analysis showed poorer survival in the high-risk group in both cohorts. The GSE192887 analysis showed significant treatment-associated expression changes in all seven genes after Pg culture-supernatant exposure. In paired tissues, CXCL8 and TMEM92 were significantly higher in OSCC tissues, whereas STC1 was not significant after Holm correction. In CAL-27 cells, CXCL8, STC1, and TMEM92 increased significantly after culture-supernatant treatment, whereas the corresponding comparisons were not significant in HOK or HSC-3 cells after adjustment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This study developed a seven-gene Pg-associated prognostic signature for OSCC and provided complementary transcriptomic, immune-correlation, tissue, and cell-based evidence that placed the signature in biological context. The model showed limited-to-moderate discrimination and is not ready for clinical use. The enrichment, gene-correlation, and immune-correlation findings are hypothesis-generating rather than mechanistic evi","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"579"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and internal validation of dual overall and cancer-specific survival nomograms for primary spinal and sacropelvic Ewing sarcoma: a population-based study of 346 patients.","authors":"Haoyu Wang, Zhenyu Shao, Ping Tang, Guanghao Li","doi":"10.21037/tcr-2026-1305","DOIUrl":"10.21037/tcr-2026-1305","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Primary spinal Ewing sarcoma (ES) is exceptionally rare, and existing prognostic evidence is largely derived from mixed-site cohorts that fail to capture the spine-specific clinical and biological profile. Accurate, site-specific prognostication remains unavailable, limiting consistency in clinical decision-making. This study aimed to define independent prognostic determinants for spinal ES and to develop and internally validate dedicated nomograms and a risk-stratification system for both overall survival (OS) and cancer-specific survival (CSS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Patients diagnosed with primary spinal ES between 1995 and 2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Prognostic variables for OS and CSS were assessed using Cox proportional hazards regression with backward stepwise selection optimized by the Akaike information criterion (AIC). Independent predictors were integrated into separate OS and CSS nomograms. Discrimination, calibration, and clinical utility were evaluated using Harrell's concordance index (C-index), time-dependent area under the receiver operating characteristic curve (AUC), calibration curves with bootstrap resampling, and decision curve analysis (DCA). A three-tier risk classification system was constructed based on total nomogram scores.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 346 eligible patients were included and randomly allocated to a training cohort (n=262) and a validation cohort (n=84) in a 3:1 ratio; 158 deaths from any cause and 142 ES-specific deaths were observed. Chemotherapy omission, distant disease and Black race/ethnicity were independent predictors of worse OS and CSS, larger tumor size was an independent predictor of worse OS, and married status was associated with lower mortality risk; the racial association, based on 10 Black patients and none in validation, is hypothesis-generating. The OS and CSS nomograms showed moderate discrimination in the training [OS C-index 0.726, 95% confidence interval (CI): 0.696-0.756; CSS 0.727, 0.697-0.757] and validation cohorts (OS 0.699, 0.640-0.758; CSS 0.680, 0.622-0.738); after 1,000-resample bootstrap internal validation the optimism-corrected C-index was 0.695 (OS) and 0.702 (CSS), with calibration slopes of 0.917 and 0.938, respectively. Calibration curves showed close agreement between predicted and observed survival. The three-tier risk classification produced well-separated survival curves for both OS and CSS, with median CSS of 197 months, 37 months, and 13 months in the low-, intermediate-, and high-risk groups, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This study provides the first dual-endpoint, site-specific prognostic framework for primary spinal and sacropelvic ES. Discrimination was moderate and validation internal only; the nomograms should be regarded as hypothesis-generating, and external validation in independent contemporary cohorts is require","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"587"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of m6A-related prognostic models for survival in lung squamous cell carcinoma with different PD-L1 expression levels.","authors":"Zonghui He, Xinjie Zhao, Guanghui Wang, Fenglong Bie","doi":"10.21037/tcr-2026-0829","DOIUrl":"10.21037/tcr-2026-0829","url":null,"abstract":"<p><strong>Background: </strong>Programmed death-ligand 1 (PD-L1) is widely used in the clinical context of immune checkpoint inhibitor therapy, but its relationship with N6-methyladenosine (m6A) RNA methylation in lung squamous cell carcinoma (LUSC) has not been well defined. This study aimed to investigate the association between PD-L1 messenger RNA (mRNA) expression and m6A regulator expression patterns and to develop exploratory m6A-based prognostic models in LUSC.</p><p><strong>Methods: </strong>Transcriptome data from 502 patients with LUSC were obtained from The Cancer Genome Atlas (TCGA). Patients were divided into PD-L1 high-expression (PHE) and PD-L1 low-expression (PLE) groups according to the median PD-L1 mRNA level. Differential expression and correlation analyses were performed for 30 m6A regulators. Transcriptome sequencing data from surgical specimens from 28 Asian patients with LUSC were used for expression-pattern comparison. Principal component analysis (PCA), univariate Cox regression, and least absolute shrinkage and selection operator (LASSO)-Cox regression were used to construct prognostic models in the TCGA cohort.</p><p><strong>Results: </strong>In the TCGA cohort, the main differentially expressed m6A regulators between the two PD-L1 groups were <i>YTHDF2</i> (P<0.001), IGF2BP3 (P<0.001), and <i>YTHDC2</i> (P<0.001). In the Asian cohort, <i>ALKBH5</i> (P=0.008) and <i>ZC3H13</i> (P=0.03) showed significant differences. LASSO-Cox models were constructed for the overall LUSC cohort and for the PHE and PLE subgroups. The overall model included <i>METTL3</i>, <i>HNRNPC</i>, and <i>CBLL1</i>, with a 5-year time-dependent area under the receiver operating characteristic curve (AUC) of 0.579. The 5-year AUCs were 0.742 in the PHE subgroup and 0.652 in the PLE subgroup. The risk score remained independently associated with prognosis in multivariate Cox analysis.</p><p><strong>Conclusions: </strong>In LUSC, PD-L1 mRNA status was associated with distinct m6A regulator expression profiles. In the TCGA cohort, the PHE subgroup showed higher expression of <i>CBLL1</i>, <i>G3BP1</i>, <i>IGF2BP3</i>, <i>FMR1</i>, and <i>YTHDC2</i>, but lower expression of <i>VIRMA</i>, <i>YTHDF2</i>, and PRRC2A compared with the PLE subgroup. In the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) cohort, <i>ALKBH5</i> and <i>ZC3H13</i> were more highly expressed in the PHE subgroup. Moreover, m6A-based risk models were associated with survival outcomes, with significant prognostic separation in the overall TCGA cohort and the PHE subgroup, whereas the PLE subgroup showed a weaker survival separation.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"598"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative magnetic resonance imaging for accurate delineation of radiotherapy: a narrative review.","authors":"Nana Li, Wei Bian, Tong Lin, Hongmei Qiao","doi":"10.21037/tcr-2026-1220","DOIUrl":"10.21037/tcr-2026-1220","url":null,"abstract":"<p><strong>Background and objective: </strong>Quantitative magnetic resonance imaging (qMRI) can provide quantifiable biological information, such as tissue relaxation times, diffusion coefficients, and perfusion parameters, thereby enabling accurate characterization of tumor heterogeneity, hypoxic status, and microenvironmental features. It holds unique clinical value in the precise delineation of radiotherapy targets. This review aims to systematically evaluate the research progress and clinical application prospects of qMRI in the biological definition of radiotherapy target volumes and to explore its potential in driving the paradigm shift from geometry-guided to biology-guided radiotherapy.</p><p><strong>Methods: </strong>This narrative review systematically searched seven databases up to January 2026. Eligible English full-text human studies focusing on qMRI and biology-guided radiotherapy target delineation were included.</p><p><strong>Key content and findings: </strong>qMRI enables the acquisition of quantitative parameters, including apparent diffusion coefficient (ADC) values, relaxation times, and perfusion metrics, which accurately reflect tumor cellularity, microvascular perfusion, and metabolic status. It demonstrates unique value in identifying tumor infiltration boundaries, delineating internal subtargets, assessing tumor hypoxia, and predicting early radiotherapy response. Currently, this technique has shown significant advantages in target delineation for tumors of the brain, head and neck, prostate, and other sites. However, key challenges remain regarding standardization of data acquisition, parameter reproducibility, multicenter validation, and deep integration with radiotherapy treatment planning systems.</p><p><strong>Conclusions: </strong>qMRI is driving a critical paradigm shift in radiotherapy from geometry-guided to biology-guided approaches, providing a powerful tool for individualized target delineation and dose \"three-dimensional sculpting\" based on tumor biology. Future efforts should focus on multi-parameter combined validation, establishing standardized systems covering acquisition, calibration, and post-processing, conducting large-scale prospective clinical trials to generate high-level evidence, and deeply integrating artificial intelligence to mine radiomics features and develop robust predictive models. Through technical optimization, clinical validation, and multidisciplinary collaboration, qMRI is expected to serve as an indispensable biological \"eye\" in precision radiotherapy systems, laying a solid foundation for individualized, adaptive radiotherapy (ART) and improved oncological outcomes.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"653"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A three-gene radioresistance signature predicts tumor progression in cervical cancer.","authors":"Hong Yu, Yuting Xiu, Fanxu Meng, Huan He, Yu Wang, Tengyu Liu, Zhicheng Wang, Zhuo Wang, Kangkang Zhao, Yunlong Wang, Zhishen Chen, Baosheng Sun","doi":"10.21037/tcr-2026-1445","DOIUrl":"10.21037/tcr-2026-1445","url":null,"abstract":"<p><strong>Background: </strong>As a primary curative treatment for locally advanced cervical cancer, radiotherapy is frequently undermined by radioresistant tumor cells that evade cell death and subsequently drive post-treatment tumor progression. This study aimed to identify candidate genes associated with radioresistance in cervical cancer and to explore their potential in predicting unfavorable outcomes among radioresistant patients, thereby providing a reference for future research.</p><p><strong>Methods: </strong>We screened for co-expressed genes using transcriptomic data from radiation non-complete response (NCR) cervical cancer patients in Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Cox regression analyses were conducted to identify the most significant radioresistance-associated genes for constructing a prognostic model. The predictive performance of this model was further validated through logistic regression, weighted gene co-expression network analysis (WGCNA), and pan-cancer analyses. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed to quantify the expression levels of key genes in cervical cancer tissue samples from radiosensitive and radioresistant patients.</p><p><strong>Results: </strong>The resulting prognostic model comprised three genes: <i>MTMR11</i>, <i>VANGL1</i>, and <i>CD46</i>. This gene panel was significantly associated with the prognosis of cervical cancer patients receiving radiotherapy and showed acceptable predictive performance across multiple cancer types. qRT-PCR analysis revealed that the expression patterns of <i>MTMR11</i> and <i>VANGL1</i> were generally consistent with radioresistance of cervical cancer, whereas <i>CD46</i> exhibited an unexpected expression trend.</p><p><strong>Conclusions: </strong>Our findings indicate that <i>MTMR11</i>, <i>VANGL1</i>, and <i>CD46</i> are associated with radioresistance and prognosis in cervical cancer. Their potential clinical utility, especially in predicting radiotherapy response at the individual patient level, requires further validation in larger, independent, and prospective cohorts.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"577"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Narrative review-the emerging role, functions, and mechanisms of UFMylation in cancers.","authors":"Lu Fang, Fan Yang","doi":"10.21037/tcr-2026-1110","DOIUrl":"10.21037/tcr-2026-1110","url":null,"abstract":"<p><strong>Background and objective: </strong>UFM1 system, i.e., UFMylation, is a newly identified post-translational modification (PTM). Increasing evidence have indicated that defects of UFMylation are implicated in multiple pathological conditions including cancers. Through this narrative review, we aim to provide a comprehensive view for development of therapeutic targets and strategies.</p><p><strong>Methods: </strong>Based on PubMed database, thorough literature research was performed to finish this narrative review. The research strategy was as follows: (ufmylation) AND ((cancer) OR (neoplasm) OR (tumor)).</p><p><strong>Key content and findings: </strong>We first summarize recently identified substrates of UFMylation. Next, we focus on and discuss reported molecular mechanisms of UFMylation in tumorigenesis and cancer treatment responses and resistance. In addition, we discuss the role and function of UFMylation in various cancers, mainly in solid tumors. Lastly, we discuss the possible crosstalk between UFMylation and ubiquitination.</p><p><strong>Conclusions: </strong>In the past decades, emerging evidence have shown that UFMylation is crucial for organ development, homeostasis maintenance, inflammation, immunity and metabolism. In addition, the defects of UFMylation, including genetic variants, abnormal expression pattern and somatic copy number alterations, have been reported involved in tumorigenesis, progression and treatment response. With in-depth investigation and research, enzymatic cascades and substrates of UFMylation will be unveiled. Promisingly, UFMylation may be utilized as a biomarker for diagnosis, treatment response assessment, and therapeutic targets in cancer therapy.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"659"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental use of angiotensin system inhibitors during neoadjuvant therapy for esophageal adenocarcinoma: an analysis of survival.","authors":"Michael Lanuti","doi":"10.21037/tcr-2026-2060","DOIUrl":"10.21037/tcr-2026-2060","url":null,"abstract":"","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"672"},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}